HR HealthCare Expands EZ Series Portfolio with EZ Protect Hydrophilic Closed System Intermittent Catheter Line
March 9, 2026
New product line extends options to better meet patient needs
New product line extends options to better meet patient needs
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it made its Mobi automated insulin delivery system available with Android devices.
Medtronic (NYSE:MDT) announced today that it launched its MiniMed Go smart multiple daily injection (MDI) system with the Simplera sensor.
Carea, a pregnancy and postnatal wellbeing app, is bridging this gap with the launch of its new Trying to Conceive: IVF/IUI Mode, to support the tens of thousands of women undergoing complex fertility treatment, amid growing concern over inconsistent clinic continuity and limited day-to-day guidance.
The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.
Staar Surgical (Nasdaq:STAA) announced that it received FDA approval for an expanded age indication for its Evo lenses.
Philips (NYSE: PHG)+ announced that it launched the InkSpace Imaging Snuggle pediatric body array coil for its 3.0T MRI systems.
BVI announced the first successful U.S. implantations of the FDA-approved FineVision HP hydrophobic trifocal intraocular lens (IOL).
PLANO, Texas, Feb. 10, 2026 /PRNewswire/ — Vesalio, a global leader in vascular intervention, today announced CE Mark certification and the European commercial launch of two new neurovascular devices: NeVa™ VS, for the treatment of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), and the NeVa™ 3.0 mm Thrombectomy System for stroke. In addition, the Company received an additional U.S. Food and Drug Administration (FDA) 510(k) clearance expanding the indications of its neurovascular and peripheral aspiration catheters to include distal access.
SAN JOSE, Calif., Feb. 5, 2026 /PRNewswire/ — LEADOPTIK, Inc., a medical technology company focused on advancing precision lung cancer biopsy, today announced the successful first-in-human clinical use of its FDA-cleared Last Inch Assessment™ (LIA) System at University of Chicago Medical Center.